Camp4 Therapeutics Poration Stock EBITDA

CAMP Stock

USD 5.37 0.18 3.24%

CAMP4 THERAPEUTICS PORATION fundamentals help investors to digest information that contributes to CAMP4 THERAPEUTICS's financial success or failures. It also enables traders to predict the movement of CAMP4 Stock. The fundamental analysis module provides a way to measure CAMP4 THERAPEUTICS's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CAMP4 THERAPEUTICS stock.

		Last Reported	Projected for Next Year
	EBITDA	-7.8 M	-7.5 M

As of 03/17/2025, EBITDA is likely to grow to about (7.5 M).

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

CAMP4 THERAPEUTICS PORATION Company EBITDA Analysis

CAMP4 THERAPEUTICS's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current CAMP4 THERAPEUTICS EBITDA

(8.72 M)

Most of CAMP4 THERAPEUTICS's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CAMP4 THERAPEUTICS PORATION is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

CAMP4 EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for CAMP4 THERAPEUTICS is extremely important. It helps to project a fair market value of CAMP4 Stock properly, considering its historical fundamentals such as EBITDA. Since CAMP4 THERAPEUTICS's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CAMP4 THERAPEUTICS's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CAMP4 THERAPEUTICS's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Good Will	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Net Invested Capital	Capital Stock	Net Working Capital
Total Assets		0.99	0.89	-0.78	0.73	0.79	-0.67	0.89	0.95	1.0	0.8	0.87	-0.89	0.97	0.73	0.96
Total Stockholder Equity	0.99		0.92	-0.84	0.8	0.7	-0.69	0.89	0.92	0.99	0.84	0.92	-0.9	0.94	0.68	0.93
Current Deferred Revenue	0.89	0.92		-0.8	0.92	0.47	-0.57	0.92	0.79	0.91	0.92	0.98	-0.9	0.75	0.62	0.77
Net Debt	-0.78	-0.84	-0.8		-0.63	-0.45	0.92	-0.62	-0.77	-0.8	-0.65	-0.82	0.85	-0.71	-0.39	-0.79
Retained Earnings	0.73	0.8	0.92	-0.63		0.22	-0.3	0.85	0.62	0.76	0.98	0.95	-0.71	0.57	0.39	0.56
Accounts Payable	0.79	0.7	0.47	-0.45	0.22		-0.51	0.54	0.85	0.77	0.32	0.41	-0.61	0.88	0.66	0.88
Net Receivables	-0.67	-0.69	-0.57	0.92	-0.3	-0.51		-0.45	-0.67	-0.67	-0.36	-0.57	0.76	-0.65	-0.42	-0.75
Good Will	0.89	0.89	0.92	-0.62	0.85	0.54	-0.45		0.75	0.89	0.91	0.9	-0.88	0.76	0.81	0.75
Total Liab	0.95	0.92	0.79	-0.77	0.62	0.85	-0.67	0.75		0.94	0.69	0.78	-0.86	0.94	0.58	0.98
Total Current Assets	1.0	0.99	0.91	-0.8	0.76	0.77	-0.67	0.89	0.94		0.81	0.89	-0.9	0.96	0.73	0.95
Short Term Debt	0.8	0.84	0.92	-0.65	0.98	0.32	-0.36	0.91	0.69	0.81		0.96	-0.78	0.64	0.48	0.64
Intangible Assets	0.87	0.92	0.98	-0.82	0.95	0.41	-0.57	0.9	0.78	0.89	0.96		-0.88	0.73	0.53	0.75
Common Stock	-0.89	-0.9	-0.9	0.85	-0.71	-0.61	0.76	-0.88	-0.86	-0.9	-0.78	-0.88		-0.77	-0.72	-0.85
Net Invested Capital	0.97	0.94	0.75	-0.71	0.57	0.88	-0.65	0.76	0.94	0.96	0.64	0.73	-0.77		0.68	0.97
Capital Stock	0.73	0.68	0.62	-0.39	0.39	0.66	-0.42	0.81	0.58	0.73	0.48	0.53	-0.72	0.68		0.65
Net Working Capital	0.96	0.93	0.77	-0.79	0.56	0.88	-0.75	0.75	0.98	0.95	0.64	0.75	-0.85	0.97	0.65

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict CAMP4 THERAPEUTICS

Ebitda Over Time

CAMP4 Ebitda

Ebitda

(7.46 Million)

CAMP4 THERAPEUTICS reported last year EBITDA of (7.85 Million)

According to the company disclosure, CAMP4 THERAPEUTICS PORATION reported earnings before interest,tax, depreciation and amortization of (8.72 Million). This is 100.94% lower than that of the Communications Equipment sector and 101.15% lower than that of the Information Technology industry. The ebitda for all United States stocks is 100.22% higher than that of the company.

CAMP4 EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CAMP4 THERAPEUTICS's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CAMP4 THERAPEUTICS could also be used in its relative valuation, which is a method of valuing CAMP4 THERAPEUTICS by comparing valuation metrics of similar companies.

CAMP4 THERAPEUTICS is currently under evaluation in ebitda category among its peers.

CAMP4 THERAPEUTICS ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, CAMP4 THERAPEUTICS's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to CAMP4 THERAPEUTICS's managers, analysts, and investors.

Environmental

Governance

Social

CAMP4 Fundamentals

	Current Valuation	109.74 M
	Shares Outstanding	20.16 M
	Shares Owned By Insiders	35.40 %
	Shares Owned By Institutions	56.95 %
	Number Of Shares Shorted	359.72 K
	Price To Earning	318.57 X
	Revenue	186.23 M
	Gross Profit	(37.93 M)
	EBITDA	(8.72 M)
	Net Income	(49.29 M)
	Cash And Equivalents	47.72 M
	Cash Per Share	1.29 X
	Total Debt	178.68 M
	Current Ratio	1.86 X
	Book Value Per Share	(158.04) X
	Cash Flow From Operations	(44.16 M)
	Short Ratio	3.48 X
	Earnings Per Share	(2.64) X
	Price To Earnings To Growth	0.08 X
	Target Price	19.91
	Number Of Employees	53
	Beta	1.89
	Market Capitalization	102.82 M
	Total Asset	54.95 M
	Retained Earnings	(159.96 M)
	Working Capital	32.21 M
	Current Asset	298.77 M
	Current Liabilities	49.56 M
	Net Asset	54.95 M

About CAMP4 THERAPEUTICS Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze CAMP4 THERAPEUTICS PORATION's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CAMP4 THERAPEUTICS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CAMP4 THERAPEUTICS PORATION based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Additional Tools for CAMP4 Stock Analysis

When running CAMP4 THERAPEUTICS's price analysis, check to measure CAMP4 THERAPEUTICS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CAMP4 THERAPEUTICS is operating at the current time. Most of CAMP4 THERAPEUTICS's value examination focuses on studying past and present price action to predict the probability of CAMP4 THERAPEUTICS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CAMP4 THERAPEUTICS's price. Additionally, you may evaluate how the addition of CAMP4 THERAPEUTICS to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC